Thyme Care Raises $125 Million as Cancer Platform Passes $2 Billion Value
CNBC reports that Thyme Care raised $125 million in a Series E round that lifted its valuation above $2 billion, while the company forms Thyme Companies to build oncology businesses beyond patient navigation.
Thyme Care raised $125 million in a Series E round that pushed the cancer-care startup's valuation above $2 billion, CNBC reported, giving the company fresh capital as it builds a broader corporate structure around oncology services.
The round was led by Morgan Health, with Humana and CVS Health Ventures joining as strategic health-care investors.
AlleyCorp, HealthQuest Capital and a16z Bio + Health also participated.
The new valuation roughly doubled Thyme Care's level from a Series D completed less than a year earlier, a fast reset for a company operating in one of health care's most expensive treatment areas.
Thyme Care launched in 2020 and ranked No. 18 on the 2026 CNBC Disruptor 50 list.
Its virtual navigation platform is designed to help patients manage the gaps that appear between cancer appointments, treatments and insurance interactions, an area co-founder Robin Shah described as “the care in between.”
The operating base has grown beyond a narrow startup pilot.
Thyme Care's services now reach a potential member base above 10.5 million people across the United States, and the company manages oncology spending of more than $7 billion.
Revenue topped $125 million last year after increasing fivefold from the prior year, giving the new parent company an operating business rather than only a funding story.
The financing coincides with a new parent company, Thyme Companies, that will sit above Thyme Care and build additional oncology-focused businesses.
Shah, who co-founded Thyme Care with Bobby Green, stepped down as chief executive in July and became executive chairman of the new parent entity.
Brad Diephuis, previously president and chief operating officer, replaced him as CEO of Thyme Care.
The handoff leaves the navigation platform under a dedicated operator while Shah works on adjacent businesses.
Two early expansion areas define the parent company's remit.
One is cancer drug affordability, including efforts to accelerate adoption of lower-cost biosimilars that are clinically equivalent to branded medicines.
Shah said cancer-focused biosimilars have not delivered as much patient savings as promised, and the company plans to work with health plans and providers on that problem.
The other initial focus is clinical-trial access and navigation.
Enrollment challenges can limit patient access to useful trials and slow drug development, and Thyme Companies expects the first of the new businesses to launch later this year.
That schedule turns the parent-company plan into a near-term operating buildout rather than a distant holding-company idea.
The funding gives the group more flexibility than it had earlier in its growth.
Shah said Thyme Care is profitable, generates positive free cash flow and has a balance sheet large enough to support investments that were not available three years ago.
Acquisitions and additional hiring remain options, while an IPO is not part of the company's near-term view.
The company's next measurable step is the launch of the first Thyme Companies business later this year.
Until then, the Series E connects a higher valuation to a specific expansion path: keeping Thyme Care focused on navigation while using the parent company to target drug costs, trial access and other gaps in oncology delivery.
